 Transferrin receptor is a promising target validated in the clinical trials for managing various malignancies . Transferrin and single chain antibody fragment can target TfR and are typically conjugated to nanomedicines

@highlight Transferrin binding peptide decorated polymersomes TBP Ps are easily obtained
@highlight TBP Ps can selectively and stably bind transferrin 
@highlight mediates targeted doxorubicin delivery to HCT 116 cancer cells
@highlight Dox loaded
@highlight effectively inhibits HCT 116 colorectal tumor
